Evidence map›Paper›PMID 35449564›Full record

ArticleFrontiers in psychiatry2022

Detection of Schizophrenia Cases From Healthy Controls With Combination of Neurocognitive and Electrophysiological Features.

Qing Tian, Ning-Bo Yang, Yu Fan, Fang Dong, Qi-Jing Bo, Fu-Chun Zhou, Ji-Cong Zhang, Liang Li, Guang-Zhong Yin, Chuan-Yue Wang and 1 more

Abstract read
In one paragraph

Article in Frontiers in psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Qing TianLaboratory of Brain Disorders, Collaborative Innovation Center for Brain Disorders, Beijing Institute of Brain Disorders, Capital Medical University, Ministry of Science and Technology, Beijing, China.
Ning-Bo YangDepartment of Psychiatry, First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.
Yu FanSuzhou Guangji Hospital, The Affiliated Guangji Hospital of Soochow University, The Institute of Mental Health, Suzhou, China.
Fang DongBeijing Key Laboratory of Mental Disorders, The National Clinical Research Center for Mental Disorders, Beijing Anding Hospital, Beijing Institute for Brain Disorders Center of Schizophrenia, Capital Medical University, Beijing, China.
Qi-Jing BoBeijing Key Laboratory of Mental Disorders, The National Clinical Research Center for Mental Disorders, Beijing Anding Hospital, Beijing Institute for Brain Disorders Center of Schizophrenia, Capital Medical University, Beijing, China.
Fu-Chun ZhouBeijing Key Laboratory of Mental Disorders, The National Clinical Research Center for Mental Disorders, Beijing Anding Hospital, Beijing Institute for Brain Disorders Center of Schizophrenia, Capital Medical University, Beijing, China.
Ji-Cong ZhangBeijing Advanced Innovation Centre for Biomedical Engineering, Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, The School of Biological Science and Medical Engineering, Beihang University, Beijing, China.
Liang LiDepartment of Psychology, Peking University, Beijing, China.
Guang-Zhong YinSuzhou Guangji Hospital, The Affiliated Guangji Hospital of Soochow University, The Institute of Mental Health, Suzhou, China.
Chuan-Yue WangBeijing Key Laboratory of Mental Disorders, The National Clinical Research Center for Mental Disorders, Beijing Anding Hospital, Beijing Institute for Brain Disorders Center of Schizophrenia, Capital Medical University, Beijing, China.
Ming FanLaboratory of Brain Disorders, Collaborative Innovation Center for Brain Disorders, Beijing Institute of Brain Disorders, Capital Medical University, Ministry of Science and Technology, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The search for a method that utilizes biomarkers to identify patients with schizophrenia from healthy individuals has occupied researchers for decades. However, no single indicator can be employed to achieve the good in clinical practice. We aim to develop a comprehensive machine learning pipeline based on neurocognitive and electrophysiological combined features for distinguishing schizophrenia patients from healthy people. Methods: In the present study, 69 patients with schizophrenia and 50 healthy controls participated. Neurocognitive (contains seven specific domains of cognition) and electrophysiological [prepulse inhibition, electroencephalography (EEG) power spectrum, detrended fluctuation analysis, and fractal dimension (FD)] features were collected, all these features were taken together to generate the identification models of schizophrenia by applying logistics, random forest, and extreme gradient boosting algorithm. The classification capabilities of these models were also evaluated. Results: Both the neurocognitive and electrophysiological feature sets showed a good classification effect with the highest accuracy greater than 85% and AUC greater than 90%. Specifically, the performances of the combined neurocognitive and electrophysiological feature sets achieved the highest accuracy of 93.28% and AUC of 97.91%. The extreme gradient boosting algorithm as a whole presented more stably and precisely in classification efficiency. Conclusion: The highest classification accuracy of 93.28% by combination of neurocognitive and electrophysiological features shows that both measurements are appropriate indicators to be used in discriminating schizophrenia patients and healthy individuals. Also, among three algorithms, extreme gradient boosting had better classified performances than logistics and random forest algorithms.

Indexed as

biomarkerclassificationelectroencephalographyelectrophysiologymachine learningneurocognitionprepulse inhibition (PPI)schizophrenia

Identifiers

PMID35449564
PMCPMC9016153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.